Home›Stock Screener›Par Drugs & Chemical›Financial Statements

Par Drugs & Chemical Complete Financial Statements

12 Years of Data
2026 - 2015

In FY2026, Par Drugs & Chemical (PAR) reported revenue ₹104 Cr, net profit ₹13 Cr and EPS ₹10.65, with a net profit margin of 12.5% and ROE of 11.6%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review PAR PE ratio trends to evaluate earnings-based valuation against sector peers.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 12.50% 2026 data
EBITDA Margin 16.35% 2026 data
Operating Margin 17.00% 2026 data
Return on Assets 10.08% 2026 data
Return on Equity 11.61% 2026 data

Balance Sheet Ratios

Current Ratio 16.00 2026 data
Equity Ratio 86.82% 2026 data
Asset Turnover 0.81 2026 data

PAR Revenue, Net Profit & EBITDA — Year-on-Year Growth

PAR YoY (March 2025 vs March 2026) — revenue +1.0%, EBITDA -22.7%, expenses +6.1%. For live price, earnings ratios and company overview, see PAR screener.

Revenue Growth
+1.0%
Year-over-Year
EBITDA Growth
-22.7%
Year-over-Year
Expense Growth
+6.1%
Year-over-Year
Assets Growth
+8.4%
Year-over-Year
Equity Growth
+13.1%
Year-over-Year
Operating Cash Flow Growth
-20.0%
Year-over-Year
Investing Cash Flow Growth
-316.7%
Year-over-Year

PAR Income Statement — Revenue, EBITDA & Net Profit

Par Drugs & Chemical revenue ₹104 Cr, EBITDA ₹17 Cr, net profit ₹13 Cr, EPS ₹10.65 (2026) — net profit margin 12.5%. Explore Par Drugs & Chemical intrinsic worth to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017
Revenue 104 103 96 96 75 61 56 46 42 49
Expenses 87 82 73 78 59 45 46 38 34 40
EBITDA 17 22 23 18 16 16 10 8 8 9
Operating Profit Margin % 17.00% 19.00% 24.00% 19.00% 22.00% 26.00% 17.00% 18.00% 19.00% 18.00%
Depreciation 4 4 3 3 3 3 3 3 3 3
Interest 0 0 0 0 1 1 1 2 2 3
Profit Before Tax 17 18 20 15 13 15 6 3 3 3
Tax 5 5 5 4 4 3 1 1 1 2
Net Profit 13 13 15 11 9 12 5 3 2 2
Earnings Per Share (₹) 10.65 10.86 11.78 9.21 7.49 18.87 7.75 5.60 5.64 6.50

PAR Balance Sheet — Assets, Liabilities & Shareholders' Equity

PAR total assets ₹129 Cr, total equity ₹112 Cr, total liabilities ₹ Cr (2026) — ROE 11.6%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017
ASSETS
Total Assets 129 119 102 89 79 76 60 51 54 56
Current Assets 64 55 60 49 44 41 24 14 14 14
Fixed Assets 37 39 41 38 34 30 34 36 39 42
Capital Work in Progress 1 0 0 0 0 5 1 0 0 0
Investments 5 25 0 0 0 0 0 0 0 0
Other Assets 0 55 60 50 44 42 25 15 15 15
LIABILITIES
Total Liabilities
Current Liabilities 4 4 4 4 4 8 9 10 16 17
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 112 99 86 71 60 52 41 29 21 20
Share Capital 12 12 12 12 12 6 6 5 9 9
Reserves & Surplus 100 87 73 59 48 46 35 25 13 11

PAR Cash Flow Statement — Operating, Investing & Financing

Par Drugs & Chemical operating cash flow ₹16 Cr, investing ₹-25 Cr, financing ₹0 Cr, net cash flow ₹-9 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities 16 20 13 8 12 8 2 4 9 7 9
Investing Activities -25 -6 -7 -3 0 -2 0 -1 -2 0 0
Financing Activities 0 0 0 -10 2 1 -2 -4 -8 -6 -9
Net Cash Flow -9 14 6 -5 14 7 0 0 -1 1 -1